THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.6]-CMP13 ID: TIP-MED-000283 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Glibenclamide IP [4.6-CMP13] — NLEM Essential Sulfonylurea & Fixed-Dose Combination Reference

Active Ingredient / Scientific Identity: Glibenclamide • Class: Second-Generation Sulfonylurea with Selective Pancreatic SUR1 Binding

⚖️ Compare Profile
Generic / Entity NameGlibenclamide (Glyburide) IP ([4.6]-CMP13)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSecond-Generation Sulfonylurea with Selective Pancreatic SUR1 Binding
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: Metabolised extensively in the liver to inactive metabolites (unlike glimepiride/glibenclamide which form active renal
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Glibenclamide (Glyburide) IP (TIP-MED-000283, Reference Code [4.6]-CMP13) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Second-Generation Sulfonylurea with Selective Pancreatic SUR1 Binding. Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-4-5). Higher risk of prolonged hypoglycaemia in CKD and the elderly compared with Gliclazide.
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-4-5). Higher risk of prolonged hypoglycaemia in CKD and the elderly compared with Gliclazide.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-4-5). Higher risk of prolonged hypoglycaemia in CKD and the elderly compared with Gliclazide.

4. Therapeutic Indications & Evidence-Supported Uses

  • Type 2 diabetes mellitus inadequately controlled by diet, exercise, and metformin (preferred sulfonylurea in elderly and mild-to-moderate CKD due to inactive renal metabolites and lower hypoglycaemia rate)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-4-5). Higher risk of prolonged hypoglycaemia in CKD and the elderly compared with Gliclazide.

Administration & Meal Timing: Take WITH breakfast (for MR once daily) or immediately before/with breakfast and dinner (for IR twice daily). | MR: Once daily with breakfast. IR (>80 mg): Divided morning and evening with meals.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [4.6].
Metabolism & Biotransformation:
Renal: Metabolised extensively in the liver to inactive metabolites (unlike glimepiride/glibenclamide which form active renal metabolites)—therefore safer in mild-to-moderate CKD (eGFR 30–60 mL/min) without dose adjustment, though hypoglycaemia vigilance remains essential; avoid if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency.
Elimination & Renal Adjustment:
Renal: Metabolised extensively in the liver to inactive metabolites (unlike glimepiride/glibenclamide which form active renal metabolites)—therefore safer in mild-to-moderate CKD (eGFR 30–60 mL/min) without dose adjustment, though hypoglycaemia vigilance remains essential; avoid if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency.
Hepatic Impairment Considerations:
Renal: Metabolised extensively in the liver to inactive metabolites (unlike glimepiride/glibenclamide which form active renal metabolites)—therefore safer in mild-to-moderate CKD (eGFR 30–60 mL/min) without dose adjustment, though hypoglycaemia vigilance remains essential; avoid if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in Type 1 DM, DKA, severe hepatic failure, severe renal failure (eGFR <15–30 mL/min), pregnancy, lactation, and concurrent miconazole therapy. Caution in G6PD deficiency.

Key Clinical Precautions: Renal: Metabolised extensively in the liver to inactive metabolites (unlike glimepiride/glibenclamide which form active renal metabolites)—therefore safer in mild-to-moderate CKD (eGFR 30–60 mL/min) without dose adjustment, though hypoglycaemia vigilance remains essential; avoid if eGFR <30 mL/min. Hepatic: Contraindicated in severe hepatic insufficiency.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Hypoglycaemia (significantly lower incidence than glibenclamide or high-dose glimepiride), mild GI upset, weight gain.
  • Severe hypoglycaemia, cholestatic hepatitis, rare haematological cytopenias, cutaneous hypersensitivity.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Miconazole (systemic or oral gel) is strictly contraindicated (causes profound, life-threatening hypoglycaemia via CYP2C9 inhibition)
    • Fluconazole, phenylbutazone, cotrimoxazole, fluoroquinolones, clarithromycin, and alcohol potentiate hypoglycaemia
    • Beta-blockers mask tachycardia/tremor signs of hypoglycaemia
    • John's Wort and rifampicin reduce gliclazide levels

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [4.6].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Verify carefully at the dispensing counter whether the prescription specifies MR/XR (30 mg or 60 mg) vs plain IR (40 mg or 80 mg). Swallow MR tablets whole (except specific scored Breakable MR tablets like Diamicron XR 60 mg, which may be halved along the score line per insert, never crushed). Always carry a glucose packet when going for morning walks.
    • Meal & Clock Timing Instruction: Take WITH breakfast (for MR once daily) or immediately before/with breakfast and dinner (for IR twice daily). (MR: Once daily with breakfast. IR (>80 mg): Divided morning and evening with meals.)
    • Missed Dose Protocol: If remembered during breakfast, take it; if breakfast is already over, skip the missed dose and resume the next scheduled dose with food.
    • Geriatric Dispensing Pearl: Recommended by WHO and Indian geriatric guidelines as the sulfonylurea of choice in elderly patients when a secretagogue is required, because of its reversible pancreatic SUR1 receptor binding, lack of active renal metabolites, and lower nocturnal hypoglycaemia rate.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Immediate-Release (IR) Scored Tablets: 40 mg, 80 mg; Modified-Release (MR / XR) Tablets: 30 mg, 60 mg

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

    Related Companion Monograph: See also the primary clinical reference monograph at /medicine/4-5-cmp12-glibenclamide-glyburide-ip/ for complementary therapeutic comparison and dosing context.